Download RTF

Publications for Mustafa Khasraw
Publications for Mustafa Khasraw
2017
Lester, A., Rapkins, R., Nixdorf, S., Khasraw,
M., McDonald, K. (2017). Combining PARP
inhibitors with radiation therapy for the treatment
of glioblastoma: Is PTEN predictive of response?
Clinical and Translational Oncology, 19(3),
273-278. <a
href="http://dx.doi.org/10.1007/s12094-016-154
7-4">[More Information]</a>
Chan, D., Pavlakis, N., Schembri, G., Bernard,
E., Diakos, C., Khasraw, M., Samra, J., Roach,
P., Bailey, D., Eslick, E., Clarke, S., Engel, A., et
al (2017). Dual Somatostatin Receptor/FDG
PET/CT Imaging in
Metastatic Neuroendocrine Tumours: Proposal
for a Novel Grading Scheme with Prognostic
Significance. Theranostics, 7(5), 1149-1158. <a
href="http://dx.doi.org/10.7150/thno.18068">[M
ore Information]</a>
Tan, A., Heimberger, A., Khasraw, M. (2017).
Immune Checkpoint Inhibitors in Gliomas.
Current Oncology Reports, 19(4). <a
href="http://dx.doi.org/10.1007/s11912-017-058
6-5">[More Information]</a>
2016
Wong, S., Norman, R., Dunning, T., Ashley, D.,
Khasraw, M., Hayes, T., Collins, I., Lorgelly, P.
(2016). A Discrete Choice Experiment to
Examine the Preferences of Patients With Cancer
and Their Willingness to Pay for Different Types
of Health Care Appointments. Journal of the
National Comprehensive Cancer Network, 14(3),
311-319.
Sajjad, M., Holloway, K., Kotowicz, M.,
Livingston, P., Khasraw, M., Hakkennes, S.,
Dunning, T., Brumby, S., Page, R., Pedler, D., et
al (2016). Ageing, Chronic Disease and Injury: A
Study in Western Victoria (Australia). Journal of
Public Health Research, 5(2), 81-86. <a
href="http://dx.doi.org/10.4081/jphr.2016.678">[
More Information]</a>
Khasraw, M., Lee, A., McCowatt, S., Kerestes,
Z., Buyse, M., Back, M., Kichenadasse, G.,
Ackland, S., Wheeler, H. (2016). Cilengitide
with metronomic temozolomide, procarbazine,
and standard radiotherapy in patients with
glioblastoma and unmethylated MGMT gene
promoter in ExCentric, an open-label phase II
trial. Journal of Neuro-Oncology, 128(1),
163-171. <a
href="http://dx.doi.org/10.1007/s11060-016-209
4-0">[More Information]</a>
Field, K., Rosenthal, M., Khasraw, M., Sawkins,
K., Nowak, A. (2016). Evolving management of
low grade glioma: No consensus amongst
treating clinicians. Journal of Clinical
Neuroscience, 23, 81-87. <a
href="http://dx.doi.org/10.1016/j.jocn.2015.05.0
38">[More Information]</a>
Segelov, E., Waring, P., Desai, J., Wilson, K.,
Gebski, V., Thavaneswaran, S., Elez, E.,
Underhill, C., Pavlakis, N., Chantrill, L.,
Khasraw, M., et al (2016). ICECREAM:
randomised phase II study of cetuximab alone or
in combination with irinotecan in patients with
metastatic colorectal cancer with either KRAS,
NRAS, BRAF and PI3KCA wild type, or G13D
mutated tumours. BMC Cancer, 16(1), 1-8. <a
href="http://dx.doi.org/10.1186/s12885-016-238
9-8">[More Information]</a>
Garber, S., Hashimoto, Y., Weathers, S., Xiu, J.,
Gatalica, Z., Verhaak, R., Zhou, S., Fuller, G.,
Khasraw, M., de Groot, J., et al (2016). Immune
checkpoint blockade as a potential therapeutic
target: surveying CNS malignancies.
Neuro-Oncology, 18(10), 1357-1366. <a
href="http://dx.doi.org/10.1093/neuonc/now132"
>[More Information]</a>
Khasraw, M., Ananda, S., Michael, M. (2016).
Neuroendocrine tumors of the gastrointestinal
tract and the role of cytotoxic chemotherapy.
Expert Review of Anticancer Therapy, 16(4),
391-401. <a
href="http://dx.doi.org/10.1586/14737140.2016.
1146135">[More Information]</a>
Hodges, T., Ferguson, S., Caruso, H.,
Kohanbash, G., Zhou, S., Cloughesy, T., Berger,
M., Poste, G., Khasraw, M., Ba, S., et al (2016).
Prioritization schema for immunotherapy clinical
trials in glioblastoma. OncoImmunology, 5(6),
1-19. <a
href="http://dx.doi.org/10.1080/2162402X.2016.
1145332">[More Information]</a>
Segelov, E., Thavaneswaran, S., Waring, P.,
Desai, J., Robledo, K., Gebski, V., Elez, E., Nott,
L., Karapetis, C., Lunke, S., Pavlakis, N.,
Khasraw, M., Wilson, K., Simes, R., et al (2016).
Response to Cetuximab With or Without
Irinotecan in Patients With Refractory Metastatic
Colorectal Cancer Harboring the KRAS G13D
Mutation: Australasian Gastro-Intestinal Trials
Group ICECREAM Study. Journal of Clinical
Oncology, 34(19), 2258-2264. <a
href="http://dx.doi.org/10.1200/JCO.2015.65.68
43">[More Information]</a>
Wong, S., Matheson, L., Morrissy, K., Pitson,
G., Ashley, D., Khasraw, M., Lorgelly, P.,
Henry, M. (2016). Retrospective analysis of
cancer survival across South-Western Victoria in
Australia. Australian Journal of Rural Health,
24(2), 79-84. <a
href="http://dx.doi.org/10.1111/ajr.12203">[Mor
e Information]</a>
Publications for Mustafa Khasraw
Li, B., Barnes, T., Chan, D., Naidoo, J., Lee, A.,
Khasraw, M., Marx, G., Kris, M., Clarke, S.,
Drilon, A., Pavlakis, N., et al (2016). The
addition of anti-angiogenic tyrosine kinase
inhibitors to chemotherapy for patients with
advanced non-small-cell lung cancers: A
meta-analysis of randomized trials. Lung Cancer,
102, 21-27. <a
href="http://dx.doi.org/10.1016/j.lungcan.2016.1
0.004">[More Information]</a>
Wann, A., Ashley, D., Khasraw, M. (2016). Use
of targeted therapy in cancer patients in the
end-of-life period: results from an Australian
centre. Supportive Care in Cancer, 24(7),
3023-3028. <a
href="http://dx.doi.org/10.1007/s00520-016-312
4-3">[More Information]</a>
2015
Dukelow, T., Kishan, D., Khasraw, M., Murphy,
C. (2015). CDK4/6 inhibitors in breast cancer.
Anti-Cancer Drugs, 26(8), 797-806. <a
href="http://dx.doi.org/10.1097/CAD.000000000
0000249">[More Information]</a>
Wang, T., Gantier, M., Xiang, D., Bean, A.,
Bruce, M., Zhou, S., Khasraw, M., Ward, A.,
Wang, L., Wei, M., et al (2015). EpCAM
Aptamer-mediated Survivin Silencing Sensitized
Cancer Stem Cells to Doxorubicin in a Breast
Cancer Model. Theranostics, 5(12), 1456-1472.
<a
href="http://dx.doi.org/10.7150/thno.11692">[M
ore Information]</a>
2014
Khasraw, M., Ameratunga, M., Grant, R.,
Wheeler, H., Pavlakis, N. (2014). Antiangiogenic
therapy for high-grade glioma. Cochrane
Database of Systematic Reviews, 2014 (9), 1-42.
<a
href="http://dx.doi.org/10.1002/14651858.CD00
8218.pub3">[More Information]</a>
Khasraw, M., Ameratunga, M., Grommes, C.
(2014). Bevacizumab for the treatment of
high-grade glioma: an update after phase III
trials. Expert Opinion on Biological Therapy,
14(5), 729-740. <a
href="http://dx.doi.org/10.1517/14712598.2014.
898060">[More Information]</a>
Hao-Wen, S., Morris, P., Patil, S., Khasraw, M.
(2014). Brain metastases in breast cancer. Expert
Review of Anticancer Therapy, 14(2), 173-183.
<a
href="http://dx.doi.org/10.1586/14737140.2014.
863468">[More Information]</a>
Ameratunga, M., Pavlakis, N., Gebski, V.,
Broad, A., Khasraw, M. (2014). Epidermal
growth factor receptor-tyrosine kinase inhibitors
in advanced squamous cell carcinoma of the
lung: a meta-analysis. Asia-Pacific Journal of
Clinical Oncology, 10(3), 273-278. <a
href="http://dx.doi.org/10.1111/ajco.12231">[M
ore Information]</a>
Gupta, S., Tran, T., Luo, W., Phung, D.,
Kennedy, R., Broad, A., Campbell, D., Kipp, D.,
Singh, M., Khasraw, M., et al (2014).
Machine-learning prediction of cancer survival: a
retrospective study using electronic
administrative records and a cancer registry.
BMJ Open, 4(3), 1-7. <a
href="http://dx.doi.org/10.1136/bmjopen-2013-0
04007">[More Information]</a>
Cosman, R., Brown, C., DeBraganca, K.,
Khasraw, M. (2014). Patterns of care in adult
medulloblastoma: results of an international
online survey. Journal of Neuro-Oncology,
120(1), 125-129. <a
href="http://dx.doi.org/10.1007/s11060-014-152
5-z">[More Information]</a>
2013
Harvey, S., Khasraw, M. (2013). Alternative
targeted therapy for early HER2 positive breast
cancer. Unknown, 2(1), 42-45.
Davis, J., Ahlberg, F., Berk, M., Ashley, D.,
Khasraw, M. (2013). Emerging pharmacotherapy
for cancer patients with cognitive dysfunction.
BMC Neurology, 13, 1-9. <a
href="http://dx.doi.org/10.1186/1471-2377-13-1
53">[More Information]</a>
Lomax, A., Yap, S., Khasraw, M. (2013).
Intraaortic metastases or intraarterial thrombus.
International Journal of Case Reports and
Images, 4(7), 368-371.
Khasraw, M., Yap, S., Ananda, S. (2013).
Neuroendocrine neoplasms of the GI tract: the
role of cytotoxic chemotherapy. Expert Review
of Anticancer Therapy, 13(4), 451-459. <a
href="http://dx.doi.org/10.1586/era.13.22">[Mor
e Information]</a>
Omuro, A., Chan, T., Abrey, L., Khasraw, M.,
Reiner, A., Kaley, T., DeAngelis, L., Lassman,
A., Nolan, C., Gavrilovic, I., et al (2013). Phase
II trial of continuous low-dose temozolomide for
patients with recurrent malignant glioma.
Neuro-Oncology, 15(2), 242-250. <a
href="http://dx.doi.org/10.1093/neuonc/nos295"
>[More Information]</a>
Domchek, S., Jhaveri, K., Patil, S., Stopfer, J.,
Hudis, C., Powers, J., Stadler, Z., Goldstein, L.,
Kauff, N., Khasraw, M., et al (2013). Risk of
metachronous breast cancer after BRCA
mutation-associated ovarian cancer. Cancer,
119(7), 1344-1348. <a
href="http://dx.doi.org/10.1002/cncr.27842">[M
ore Information]</a>
Publications for Mustafa Khasraw
Mustafa, B., Samaan, M., Langmead, L.,
Khasraw, M. (2013). Small bowel video capsule
endoscopy: an overview. Expert Review of
Gastroenterology and Hepatology, 7(4),
323-329. <a
href="http://dx.doi.org/10.1586/egh.13.20">[Mo
re Information]</a>
2012
Khasraw, M., Simeonovic, M., Grommes, C.
(2012). Bevacizumab for the treatment of
high-grade glioma. Expert Opinion on Biological
Therapy, 12(8), 1101-1111. <a
href="http://dx.doi.org/10.1517/14712598.2012.
694422">[More Information]</a>
Sheet, S., Sheikha, A., Saeed, A., Ameen, H.,
Mohammed, S., Khasraw, M. (2012). Colorectal
cancer: is the incidence rising in young Iraqi
patients? Asia-Pacific Journal of Clinical
Oncology, 8(4), 380-381. <a
href="http://dx.doi.org/10.1111/j.1743-7563.201
2.01524.x">[More Information]</a>
Khasraw, M., Bell, R., Dang, C. (2012).
Epirubicin: Is it like doxorubicin in breast
cancer? A clinical review. The Breast, 21(2),
142-149. <a
href="http://dx.doi.org/10.1016/j.breast.2011.12.
012">[More Information]</a>
Khasraw, M., Harvey, S., Bell, R. (2012).
Hormonal Resistance in Breast Cancer: Evolving
Treatment Strategies. Current Breast Cancer
Reports, 4(1), 66-74. <a
href="http://dx.doi.org/10.1007/s12609-011-006
5-1">[More Information]</a>
Khasraw, M., Holodny, A., Goldlust, S.,
DeAngelis, L. (2012). Intracranial hemorrhage in
patients with cancer treated with bevacizumab:
the Memorial Sloan-Kettering experience.
Annals of Oncology, 23(2), 458-463. <a
href="http://dx.doi.org/10.1093/annonc/mdr148"
>[More Information]</a>
Khasraw, M., Noy, A., Gilbert, M., Omuro, A.
(2012). Neurological Complications of
Non-Hodgkin Lymphoma. In Tracy Batchelor,
Lisa M DeAngelis (Eds.), Lymphoma and
Leukemia of the Nervous System, (pp. 267-286).
New York: Springer Science+Business Media.
<a
href="http://dx.doi.org/10.1007/9781441976680
_16">[More Information]</a>
Khasraw, M., Khakoo, Y. (2012). Paraneoplastic
Syndromes Affecting the Nervous System. In
Kenneth F. Swaiman, Stephen Ashwal, Donna M
Ferriero, Nina F Schor (Eds.), Swaiman's
Pediatric Neurology: Principles and Practice,
5th Ed, (pp. 1388-1394). Canada: Elsevier Inc.
Khasraw, M., Bell, R. (2012). Primary systemic
therapy in HER2-amplified breast cancer: a
clinical review. Expert Review of Anticancer
Therapy, 12(8), 1005-1013. <a
href="http://dx.doi.org/10.1586/era.12.62">[Mor
e Information]</a>
Khasraw, M., Ashley, D., Wheeler, G., Berk, M.
(2012). Using lithium as a neuroprotective agent
in patients with cancer. BMC Medicine, 10, 1-7.
<a
href="http://dx.doi.org/10.1186/1741-7015-10-1
31">[More Information]</a>
2011
Khasraw, M., Robson, M. (2011).
Poly(ADP-ribose) polymerase inhibitors in
breast cancer and other tumors: advances and
challenges. Clinical Investigation, 1(11),
1545-1554. <a
href="http://dx.doi.org/10.4155/cli.11.132">[Mo
re Information]</a>
Khasraw, M., Brogi, E., Seidman, A. (2011). The
Need to Examine Metastatic Tissue at the Time
of Progression of Breast Cancer: Is Re-biopsy a
Necessity or a Luxury? Current Oncology
Reports, 13(1), 17-25. <a
href="http://dx.doi.org/10.1007/s11912-010-013
7-9">[More Information]</a>
2010
Khasraw, M., Lassman, A. (2010). Advances in
the Treatment of Malignant Gliomas. Current
Oncology Reports, 12(1), 26-33. <a
href="http://dx.doi.org/10.1007/s11912-009-007
7-4">[More Information]</a>
Khasraw, M., Lassman, A., Wheeler, H.,
Pavlakis, N. (2010). Anti-angiogenic therapy for
high grade glioma (Protocol). Cochrane
Database of Systematic Reviews, 2010 (2), 1-9.
Murphy, C., Khasraw, M., Seidman, A. (2010).
Holding back the sea: the role for maintenance
chemotherapy in metastatic breast cancer. Breast
Cancer Research and Treatment, 122(1),
177-179. <a
href="http://dx.doi.org/10.1007/s10549-010-092
5-9">[More Information]</a>
Khasraw, M., Pavlakis, N., McCowatt, S.,
Underhill, C., Begbie, S., De Souza, P., Boyce,
A., Parnis, F., Lim, V., Harvie, R., et al (2010).
Multicentre phase I/II study of PI-88, a
heparanase inhibitor in combination with
docetaxel in patients with metastatic
castrate-resistant prostate cancer. Annals of
Oncology, 21(6), 1302-1307. <a
href="http://dx.doi.org/10.1093/annonc/mdp524"
>[More Information]</a>
Khasraw, M., Posner, J. (2010). Neurological
complications of systemic cancer. The Lancet
Neurology, 9(12), 1214-1227. <a
href="http://dx.doi.org/10.1016/S1474-4422(10)
Publications for Mustafa Khasraw
70220-9">[More Information]</a>
Khasraw, M., Townsend, A., Price, T., Hart, J.,
Bell, D., Pavlakis, N. (2010). Objective
radiological disease control with Sandostatin
monotherapy in metastatic neuroendocrine
tumours. Internal Medicine Journal, 40(6),
453-458. <a
href="http://dx.doi.org/10.1111/j.1445-5994.201
0.02245.x">[More Information]</a>
Khasraw, M., Faraj, H., Sheikha, A. (2010).
Thrombocytopenia in Solid Tumors. European
Journal of Clinical & Medical Oncology, 2(2),
1-4.
2009
Khasraw, M., Atkinson, C., Van der Saag, D.,
Pavlakis, N., Guminski, A. (2009). Cardiac
toxicity from sunitinib: Do we need to be more
vigilant? Asia-Pacific Journal of Clinical
Oncology, 5(4), 217-218. <a
href="http://dx.doi.org/10.1111/j.1743-7563.200
9.01243.x">[More Information]</a>
Khasraw, M., Baron-Hay, S. (2009). Immune
thrombocytopenic purpura (ITP) and breast
cancer. Does adjuvant therapy for breast cancer
improve platelet counts in ITP? Annals of
Oncology, 20(7), 1282-1283. <a
href="http://dx.doi.org/10.1093/annonc/mdp305"
>[More Information]</a>
Khasraw, M., Bell, D., Wheeler, H. (2009).
Long-term use of temozolomide: Could you use
temozolomide safely for life in gliomas? Journal
of Clinical Neuroscience, 16(6), 854-855. <a
href="http://dx.doi.org/10.1016/j.jocn.2008.09.0
05">[More Information]</a>
Khasraw, M., Gill, A., Harrington, T., Pavlakis,
N., Modlin, I. (2009). Management of Advanced
Neuroendocrine Tumors With Hepatic
Metastasis. Journal of Clinical
Gastroenterology, 43(9), 838-47. <a
href="http://dx.doi.org/10.1097/MCG.0b013e31
81b152a1">[More Information]</a>
Khasraw, M., Lassman, A. (2009).
Neuro-oncology: late neurocognitive decline
after radiotherapy for low-grade glioma. Nature
Reviews Neurology, 5(12), 646-647. <a
href="http://dx.doi.org/10.1038/nrneurol.2009.19
4">[More Information]</a>
2008
Khasraw, M., Marx, G. (2008). Chemotherapy in
the Elderly. Cancer Forum, 32(1), 1-4.